191 related articles for article (PubMed ID: 34958922)
1. Prevalence of High-risk Nonalcoholic Steatohepatitis (NASH) in the United States: Results From NHANES 2017-2018.
Vilar-Gomez E; Vuppalanchi R; Mladenovic A; Samala N; Gawrieh S; Newsome PN; Chalasani N
Clin Gastroenterol Hepatol; 2023 Jan; 21(1):115-124.e7. PubMed ID: 34958922
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and factors associated with NAFLD detected by vibration controlled transient elastography among US adults: Results from NHANES 2017-2018.
Zhang X; Heredia NI; Balakrishnan M; Thrift AP
PLoS One; 2021; 16(6):e0252164. PubMed ID: 34081733
[TBL] [Abstract][Full Text] [Related]
4. FibroScan-AST (FAST) Score for Nonalcoholic Steatohepatitis - Validation in an Indian Cohort.
De A; Keisham A; Mishra S; Mehta M; Verma N; Premkumar M; Taneja S; Das A; Singh V; Duseja A
J Clin Exp Hepatol; 2022; 12(2):440-447. PubMed ID: 35535068
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of at-risk NASH and its association with metabolic syndrome in US adults with NAFLD, 2017-2018.
Payne JY; Alkhouri N; Le P; Rothberg MB; Polanco P; Sakkal C; Dasarathy S
Hepatol Commun; 2023 Jan; 7(1):e0019. PubMed ID: 36633494
[TBL] [Abstract][Full Text] [Related]
6. Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms.
Woreta TA; Van Natta ML; Lazo M; Krishnan A; Neuschwander-Tetri BA; Loomba R; Mae Diehl A; Abdelmalek MF; Chalasani N; Gawrieh S; Dasarathy S; Vuppalanchi R; Siddiqui MS; Kowdley KV; McCullough A; Terrault NA; Behling C; Kleiner DE; Fishbein M; Hertel P; Wilson LA; Mitchell EP; Miriel LA; Clark JM; Tonascia J; Sanyal AJ;
PLoS One; 2022; 17(4):e0266859. PubMed ID: 35427375
[TBL] [Abstract][Full Text] [Related]
7. Noninvasive identification of probable fibrotic nonalcoholic steatohepatitis across the spectrum of glucose tolerance in the United States.
Ciardullo S; Carbone M; Invernizzi P; Perseghin G
Diabetes Res Clin Pract; 2023 May; 199():110679. PubMed ID: 37094749
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and risk factors of nonalcoholic fatty liver disease, high-risk nonalcoholic steatohepatitis, and fibrosis among lean United States adults: NHANES 2017-2020.
Kalligeros M; Vassilopoulos S; Vassilopoulos A; Shehadeh F; Lazaridou I; Mylonakis E; Promrat K; Wands JR
Ann Gastroenterol; 2023; 36(6):670-677. PubMed ID: 38023978
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis.
Sagara M; Iijima T; Kase M; Kato K; Sakurai S; Tomaru T; Jojima T; Usui I; Aso Y
J Diabetes Complications; 2021 May; 35(5):107885. PubMed ID: 33602617
[TBL] [Abstract][Full Text] [Related]
10. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
Newsome PN; Sasso M; Deeks JJ; Paredes A; Boursier J; Chan WK; Yilmaz Y; Czernichow S; Zheng MH; Wong VW; Allison M; Tsochatzis E; Anstee QM; Sheridan DA; Eddowes PJ; Guha IN; Cobbold JF; Paradis V; Bedossa P; Miette V; Fournier-Poizat C; Sandrin L; Harrison SA
Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):362-373. PubMed ID: 32027858
[TBL] [Abstract][Full Text] [Related]
11. Predicting NAFLD prevalence in the United States using National Health and Nutrition Examination Survey 2017-2018 transient elastography data and application of machine learning.
Noureddin M; Ntanios F; Malhotra D; Hoover K; Emir B; McLeod E; Alkhouri N
Hepatol Commun; 2022 Jul; 6(7):1537-1548. PubMed ID: 35365931
[TBL] [Abstract][Full Text] [Related]
12. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.
Bazick J; Donithan M; Neuschwander-Tetri BA; Kleiner D; Brunt EM; Wilson L; Doo E; Lavine J; Tonascia J; Loomba R
Diabetes Care; 2015 Jul; 38(7):1347-55. PubMed ID: 25887357
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic accuracy of FibroScan-AST (FAST) score for the non-invasive identification of patients with fibrotic non-alcoholic steatohepatitis: a systematic review and meta-analysis.
Ravaioli F; Dajti E; Mantovani A; Newsome PN; Targher G; Colecchia A
Gut; 2023 Jul; 72(7):1399-1409. PubMed ID: 36599683
[TBL] [Abstract][Full Text] [Related]
14. The prevalence of alcoholic and nonalcoholic fatty liver disease in adolescents and young adults in the United States: analysis of the NHANES database.
Alkhouri N; Almomani A; Le P; Payne JY; Asaad I; Sakkal C; Vos M; Noureddin M; Kumar P
BMC Gastroenterol; 2022 Jul; 22(1):366. PubMed ID: 35907827
[TBL] [Abstract][Full Text] [Related]
15. Prepandemic Prevalence Estimates of Fatty Liver Disease and Fibrosis Defined by Liver Elastography in the United States.
Unalp-Arida A; Ruhl CE
Dig Dis Sci; 2023 Apr; 68(4):1237-1252. PubMed ID: 36173583
[TBL] [Abstract][Full Text] [Related]
16. Human Immunodeficiency Virus Is Associated With Elevated FibroScan-Aspartate Aminotransferase (FAST) Score.
Price JC; Ma Y; Kuniholm MH; Adimora AA; Fischl M; French AL; Golub ET; Konkle-Parker D; Minkoff H; Ofotokun I; Plankey M; Sharma A; Tien PC
Clin Infect Dis; 2022 Dec; 75(12):2119-2127. PubMed ID: 35511608
[TBL] [Abstract][Full Text] [Related]
17. Severity of metabolic syndrome is greater among nonalcoholic adults with elevated ALT and advanced fibrosis.
DeBoer MD; Lin B; Filipp SL; Cusi K; Gurka MJ
Nutr Res; 2021 Apr; 88():34-43. PubMed ID: 33743323
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of a novel non-invasive test for diagnosing fibrotic non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease.
Gao F; Huang JF; Zheng KI; Pan XY; Ma HL; Liu WY; Byrne CD; Targher G; Li YY; Chen YP; Chan WK; Zheng MH
J Gastroenterol Hepatol; 2020 Oct; 35(10):1804-1812. PubMed ID: 32246876
[TBL] [Abstract][Full Text] [Related]
19. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
[TBL] [Abstract][Full Text] [Related]
20. Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography.
Lai LL; Wan Yusoff WNI; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
J Gastroenterol Hepatol; 2019 Aug; 34(8):1396-1403. PubMed ID: 30551263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
